CYP3A4 and chronic kidney disease: Correspondingly no dose adjustments are recommended for patients with impaired kidney function (Novartis Pharma, 2011) implicating that changes of CYP3A4 expression in chronic kidney disease are of minor pharmacokinetic relevance for cyclosporine.